Adaptive Biotechnologies Corpor (ADPT) concentration risks

Adaptive Biotechnologies carries two high-share concentrations that together define a profile of compounded dependency: one on the revenue side and one on the supply side. On the commercial front, the company's MRD revenue is anchored in its clonoSEQ product, which drove $212.3 million in MRD revenue in 2025 alongside a reported volume of 105,587 tests. The filing characterizes this as a mixed exposure — part structural (the product serves an established clinical need in oncology) and part dependency (revenue is concentrated in a single assay whose continued commercial success depends on adoption, reimbursement, and competitive positioning). On the supply side, Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System and the NovaSeq X Plus System — the sequencing platforms on which clonoSEQ testing depends. This is a high-share dependency with a clear idiosyncratic character: an interruption in Illumina's service provision, a change in contractual terms, or a platform transition would have no available substitute and could directly impair testing capacity. The two exposures reinforce each other in the adverse scenario: the product concentration means the company's revenue stream is narrow, and the supplier dependency means that narrow revenue stream runs through a single vendor's hardware ecosystem. Together they define the two variables most worth monitoring in assessing the durability of the company's commercial model.

For the engine’s reasoning on ADPT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.